Regio- and stereospecific N-glucuronidation of medetomidine:: The differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes

被引:53
作者
Kaivosaari, Sanna [2 ,3 ,4 ]
Toivonen, Paivi [2 ,3 ,4 ]
Aitio, Olli [5 ]
Sipila, Julius [2 ,3 ,4 ]
Koskinen, Mikko [2 ,3 ]
Salonen, Jarmo S. [2 ,3 ]
Finel, Moshe [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Ctr Drug Res, FIN-00014 Helsinki, Finland
[2] Orion Corp Farmos, Orion Pharma, Res & Dev, Espoo, Finland
[3] Orion Corp Farmos, Orion Pharma, Res & Dev, Turku, Finland
[4] Univ Helsinki, Div Pharmaceut Chem, Fac Pharm, FIN-00014 Helsinki, Finland
[5] Univ Helsinki, Program Struct Biol & Biophys, Inst Biotechnol, Nucl Magnet Resonance Lab, FIN-00014 Helsinki, Finland
关键词
D O I
10.1124/dmd.108.021709
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medetomidine is a chiral imidazole derivate whose dextroenantiomer is pharmacologically active. The major metabolic pathway of dexmedetomidine [(+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] in humans is N-glucuronidation at the imidazolate nitrogens. We have purified the N-3- and N-1 -glucuronides of dexmedetomidine, termed DG1 and DG2, respectively, according to their elution order in liquid chromatography and determined their structure by H-1 nuclear magnetic resonance (NMR). Studying medetomidine glucuronidation by human liver microsomes (HLMs) and recombinant UDP glucuronosyltransferase (UGT) 1A4 indicated that another human UGT plays a major role in these activities. We now demonstrate that this enzyme is UGT2B10. HLMs catalyzed DG1 and DG2 formation, at a ratio of 3: 1, with two-enzyme kinetics that contain both a high-affinity component, K-m1 values of 6.6 and 8.7 mu M, and a low-affinity component, K-m2 values > 1 mM. The DG1/DG2 ratio in the case of UGT2B10 was lower, 1.4:1, whereas the substrate affinity for both reactions was high, K-m values of 11 and 16 mu M. UGT1A4 produced mainly DG1 (DG1/DG2 ratio of 6.6: 1) at low substrate affinities, K-m values above 0.6 mM, but superior expression-normalized V-max values. Levomedetomidine [( -)-4-( R)-[ 1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] glucuronidation by HLMs yielded mostly the N-3- glucuronide (LG1, structure determined by NMR), with monophasic kinetics and a K-m value of 14 mu M. The activity of UGT1A4 toward levomedetomide was low and generated both LG1 and LG2, whereas UGT2B10 exhibited relatively high activity and sharp regioselectivity, yielding only LG1, with a K-m value of 7.4 mu M. The results highlight the contribution of UGT2B10 to medetomidine glucuronidation and its potential importance for other N-glucuronidation reactions within the human liver.
引用
收藏
页码:1529 / 1537
页数:9
相关论文
共 33 条
[1]  
Ansah OB, 2000, J VET PHARMACOL THER, V23, P1, DOI 10.1046/j.1365-2885.2000.00240.x
[2]   Dexmedetomidine [J].
Bhana, N ;
Goa, KL ;
McClellan, KJ .
DRUGS, 2000, 59 (02) :263-268
[3]   N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II [J].
Borlak, Jurgen ;
Gasparic, Antje ;
Locher, Mathias ;
Schupke, Hubert ;
Hermann, Robert .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (06) :711-721
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
Breyer-Pfaff U, 2000, DRUG METAB DISPOS, V28, P869
[6]   Glucuronidation of nicotine and cotinine by UGT2B10:: Loss of function by the UGT2B10 codon 67 (Asp>Tyr) polymorphism [J].
Chen, Gang ;
Blevins-Primeau, Andrea S. ;
Dellinger, Ryan W. ;
Muscat, Joshua E. ;
Lazarus, Philip .
CANCER RESEARCH, 2007, 67 (19) :9024-9029
[7]  
Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, V2
[8]  
Fisher MB, 2000, DRUG METAB DISPOS, V28, P560
[9]   UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver [J].
Girard, H ;
Thibaudeau, J ;
Court, MH ;
Fortier, LC ;
Villeneuve, L ;
Carom, P ;
Hao, Q ;
von Moltke, LL ;
Greenblatt, DJ ;
Guillemette, C .
HEPATOLOGY, 2005, 42 (02) :448-457
[10]  
Green MD, 1998, DRUG METAB DISPOS, V26, P860